FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer By Ogkologos - January 22, 2026 443 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel June 28, 2021 FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL July 29, 2021 ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 ΤΙ ΕΙΝΑΙ January 18, 2019 Load more HOT NEWS FDA Approves Blood Tests That Can Help Guide Cancer Treatment Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection... Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage...
